Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling a
- PDF / 1,878,462 Bytes
- 25 Pages / 595.276 x 790.866 pts Page_size
- 83 Downloads / 151 Views
REVIEW ARTICLE
Sphingosine 1‑phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects Jerold Chun1 · Gavin Giovannoni2 · Samuel F. Hunter3
© The Author(s) 2020
Abstract Lysophospholipids are a class of bioactive lipid molecules that produce their effects through various G protein-coupled receptors (GPCRs). Sphingosine 1-phosphate (S1P) is perhaps the most studied lysophospholipid and has a role in a wide range of physiological and pathophysiological events, via signalling through five distinct GPCR subtypes, S 1PR1 to S 1PR5. Previous and continuing investigation of the S1P pathway has led to the approval of three S1PR modulators, fingolimod, siponimod and ozanimod, as medicines for patients with multiple sclerosis (MS), as well as the identification of new S1PR modulators currently in clinical development, including ponesimod and etrasimod. S1PR modulators have complex effects on S1PRs, in some cases acting both as traditional agonists as well as agonists that produce functional antagonism. S1PR subtype specificity influences their downstream effects, including aspects of their benefit:risk profile. Some S1PR modulators are prodrugs, which require metabolic modification such as phosphorylation via sphingosine kinases, resulting in different pharmacokinetics and bioavailability, contrasting with others that are direct modulators of the receptors. The complex interplay of these characteristics dictates the clinical profile of S1PR modulators. This review focuses on the S1P pathway, the characteristics and S1PR binding profiles of S1PR modulators, the mechanisms of action of S1PR modulators with regard to immune cell trafficking and neuroprotection in MS, together with a summary of the clinical effectiveness of the S1PR modulators that are approved or in late-stage development for patients with MS. Jerold Chun, Gavin Giovannoni and Samuel F. Hunter have all contributed equally. Enhanced Digital Features To view enhanced digital features for this article, go to https://doi.org/10.6084/m9.figshare.13133288. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40265-020-01431-8) contains supplementary material, which is available to authorized users. * Gavin Giovannoni [email protected] Jerold Chun [email protected] Samuel F. Hunter [email protected] 1
Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
2
Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, London E1 2AT, UK
3
Advanced Neurosciences Institute, 101 Forrest Crossing Blvd STE 103, Franklin, TN 37064, USA
1 Introduction Lysophospholipids are a class of bioactive lipid molecules that produce their effects through a large number of G protein-coupled receptors (GPCRs). The lysophospholipid receptor family is characterised according to its specific ligands, which include the l
Data Loading...